U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

A YOUNG mum battling a rare form of cancer passed away surrounded by loved ones after suffering complications from treatment.

Cutaneous chronic graft-versus-host disease reduces quality of life through skin symptoms and broader impacts, guiding ...

Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.

Let’s cover six scientifically backed methods to address the post-stem cell transplant procedure side effects you may be ...

In some cases, sexually transmitted infections (STIs) cause no noticeable symptoms. When they do occur, STI symptoms in males can include discharge, bleeding, painful blisters, and more.

TRX-103 is under clinical development by Tr1X and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% ...

SER-155 is under clinical development by Seres Therapeutics and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) ...

I am excited about the potential for tissue or blood biomarkers to direct patients toward a specific treatment based on the underlying mechanism driving their GVHD symptoms. You were one of the ...

It’s probably been a minute since you last thought about COVID-19, making it natural to wonder about its symptoms in 2024. Are they any different? The same? Of course, if you're feeling sick ...